Article thumbnail

Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies

By Andrea Ries Thurman, Meredith R. Clark and Gustavo F. Doncel


Statistics clearly show an unmet need for highly effective contraception, especially in less developed countries. Many of these countries are at the core of the HIV/AIDS epidemic and show very high prevalence rates for other sexually transmitted infections (STIs) such as that caused by HSV-2. A woman at risk of unintended pregnancy due to unprotected intercourse is also at risk for HIV/STI. Owing to their causative interrelationship, combining protection against these conditions will result in enhanced prevention and health benefits. Existing multipurpose prevention modalities such as condoms and physical barriers, albeit efficacious, face cultural hurdles that have so far hindered their widespread use. Success has recently been demonstrated in large clinical trials, demonstrating proof of concept of microbicides in reducing the incidence of HIV-1 and HSV-2 among at-risk populations. The challenge heretofore is to refine these products to make them more potent, convenient, accessible, and acceptable. Potent antiviral drugs released topically in the female reproductive tract by innovative delivered systems and formulations will provide safe, effective, and acceptable multipurpose prevention tools. This paper provides an overview of existing and novel approaches to multipurpose prevention strategies

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). Abortion Worldwide: A Decade of Uneven Progress, Guttmacher Institute,
  2. (2010). Acyclovir and transmissionofHIV-1frompersonsinfectedwithHIV-1and HSV-2,” The New England
  3. (2005). Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women,”
  4. (2002). Alary et al., “Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial,”
  5. (2011). Antiretroviral/zinc combination gel provides 24hours of complete protection against vaginal SHIV infection in macaques,”
  6. (2006). Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru,”
  7. (2009). Azijn et al., “Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor,”
  8. (2009). B o i l y ,R .F .B a g g a l e y ,L .W a n ge ta l . ,“ H e t e r o s e x u a l risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies,” The Lancet Infectious Diseases,
  9. (2008). B.VanDerPol,C.Kwok,B.Pierre-Louisetal.,“Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women,”
  10. (2005). Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study,”JournalofInfectiousDiseases,vol.192,no.8,pp.1372– 1380,
  11. (1992). Barrier contraceptives and sexually transmitted diseases in women: a comparison of femaledependent methods and condoms,”
  12. (2000). BufferGel is an Active Spermicide in the Standardized Postcoital Test,M i c r o b i c i d e s ,
  13. (2006). Carrageenan is a potent inhibitor of papillomavirus infection,”
  14. (2005). Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection,”
  15. (2001). Chany II et al., “Properties of a new acid-buffering bioadhesive vaginal formulation
  16. (2006). Choice is empowering: getting strategic about preventing HIV infection in women,”
  17. (1960). Contraceptive efficacy and acceptability of the female condom,”
  18. (2010). Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial,”
  19. (2008). Cornelisse et al., “Bacterial vaginosis and vaginal yeast, but not vaginal cleansing,
  20. (2006). Countrywide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis,”
  21. (1998). Dallabetta et al., “Bacterial vaginosis and disturbances of vaginal flora: association with increasedacquisitionofHIV,”AIDS,vol.12,no.13,pp.1699– 1706,
  22. (2006). Dawn of non-nucleoside inhibitor-based anti-HIV microbicides,”
  23. (2007). Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial,”
  24. (2001). Diaphragm versus diaphragm with spermicides for contraception,” Cochrane Database of Systematic Reviews,
  25. (2009). Disentanglingcontributionsofreproductivetractinfections to hiv acquisition
  26. e l a g h a n ,G .L .R u b i n ,H .W .O r y ,a n dP .M .L a y d e , “Barrier-method contraceptives and pelvic inflammatory
  27. (2007). Eds., Contraceptive Technology,
  28. (1998). Eds., Textbook of Pediatric Infectious Diseases,
  29. (2009). Effect of acculturation on the acceptability of potential microbicides and sexual risk-taking,” Sexually Transmitted Diseases,
  30. (2008). Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial,”
  31. (2008). Effect of herpes simplex suppression on incidence of HIV among women in Tanzania,” The New England
  32. (2008). Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial
  33. (2005). Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions,” Sexually Transmitted Infections,v o l .8 1 ,n o .3 ,p p .
  34. (1977). Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebocontrolled trial,”
  35. (2010). Efficacy of contraceptive methods: a review of the literature,”
  36. (2004). Epidemiology of herpes simplex virus type 2 infection in the developing world,” Herpes,
  37. (2003). Expanding safer sex options: introducing the female condom into national programmes,”
  38. (2003). F r e n c h ,M .L a t k a ,E .L .G o l l u b ,C .R o g e r s ,D .R .H o o v e r
  39. (2011). Free condoms at gay nightspots,” The Bangkok Post,
  40. (2006). Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies,”
  41. (2008). Herpes simplex virus and HIV-1: deciphering viral synergy,” The Lancet Infectious Diseases,
  42. (2004). HIV topical microbicides: the current development strategy is fully justified,”
  43. (2000). Iliff et al., “Effect of intravaginal practices on the vaginal and cervical mucosa of Zimbabweanwomen,”JournalofAcquiredImmuneDeficiency Syndromes,
  44. (2002). In vitro antiviral activity of dermaseptins against herpes simplex virus type 1,”
  45. (2007). Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition,”
  46. (1999). Inhibition of HIV-1 infection by zinc group metal compounds,”
  47. (2010). Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition,”
  48. (2005). Intravaginal practices, bacterial vaginosis, and women’s susceptibilitytoHIVinfection:epidemiologicalevidenceand
  49. (1994). J.Trussell,K.Sturgen,J.Strickler,andR.Dominik,“Comparative contraceptive efficacy of the female condom and other barrier methods,” Family Planning Perspectives,
  50. (2007). J.Zhu,D.M.Koelle,J.Caoetal.,“Virus-specificCD8+ Tc ells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation,”
  51. (1999). K.R.DavisandS.C.Weller,“Theeffectivenessofcondomsin reducing heterosexual transmission of HIV,” Family Planning Perspectives,
  52. (2007). L.Peterson,K.Nanda,B.K.Opokuetal.,“SAVVY(C31G)gel forpreventionofHIVinfectioninwomen:aphase3,doubleblind, randomized, placebo-controlled trial in
  53. (2008). Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal
  54. (1979). Lowlevel, progestogen-releasing vaginal contraceptive devices,”
  55. (2004). m a r a l ,A .P e r d i g a o ,M .H .S o u z a ,C .M a u c k ,D .W a l l e r , L. Zaneveld et al., “Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product,”
  56. McDougal et al., “Inactivation of HTLVIII/LAV-infected cultures of normal human lymphocytes by nonoxynol-9
  57. (1990). Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. world health organization. Task force on long-acting systemic agents for fertility regulation,”
  58. (1990). Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. world health organization. Task force on long-acting systemic agents for fertility regulation,”
  59. (1990). Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. world health organization. Task force on long-acting systemic agents for fertility regulation,”
  60. Negative mucosal synergy between Herpes simplex type 2 and HIV in t h ef e m a l eg e n i t a lt r a c t
  61. (2006). Non-latex versus latex male condoms for contraception,” Cochrane Database of Systematic Reviews,n o .1 ,A r t i c l eI D CD003550,
  62. (1993). Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study,”
  63. (2008). Noncomparative contraceptive efficacy of cellulose sulfate gel,”
  64. (1988). o l s k y ,P .A .B a r o n
  65. (2002). Organization, The Safety and Feasibility of Female Condom Reuse: Report of a WHO Consultation,W o r l d Health Organization,
  66. (2009). Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition,”
  67. (1985). Pharmacokinetic andpharmacodynamic studiesofvaginalringsreleasinglowdose levonorgestrel,”
  68. (2010). Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women,”
  69. (2010). Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety Vs. Hydroxyethyl cellulosebased universal placebo gel,”
  70. Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis,”
  71. (2008). Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1,”JournalofPharmaceuticalSciences,vol.97,no.10,pp. 4228–4239,
  72. (2001). Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices,”
  73. (2010). PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial,”
  74. (2010). Q.A.Karim,S.S.A.Karim,J.A.Frohlichetal.,“Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women,”
  75. (2009). Q.Li,J.D.Estes,P.M.Schlievertetal.,“Glycerolmonolaurate prevents mucosal SIV transmission,”
  76. (1998). Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission,”
  77. (2002). Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis,”
  78. (2009). Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring,”
  79. (2011). Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection
  80. (2009). Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women,”
  81. (2008). SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial
  82. (2010). Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir,”
  83. (2007). Sex-structured HIV/AIDS model to analyse the effects of condom use with application to
  84. (2010). Sexual Health and Responsibility Program.
  85. (2008). SILCS diaphragm: postcoital testing of a new single-size contraceptive device,”
  86. (2005). Spermicidal activity of dermaseptins,”
  87. (2010). Synthesis, antiviral and contraceptive activities of nucleosidesodium cellulose sulfate acetate and succinate conjugates,”
  88. (2008). The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial,”
  89. (1998). The effect of nonoxynol-9 and chlorhexidine on HIV and sperm in vitro,”
  90. (1993). The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro,”
  91. (1990). The mechanism of the antiherpetic activity of zinc sulphate,”
  92. (2000). The rate at which human sperm are immobilized and killed by mild acidity,”
  93. (2007). The search for a topical dual action spermicide/microbicide,”
  94. (2007). UNFPA and the World Bank. Maternal Mortality in 2005: Estimates developed by WHO, UNICEF, UNFPA and the World Bank.
  95. (1999). Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition,”
  96. (2009). World Health Organization, 09 AIDS Epidemic Update,
  97. (2009). World Health Organization, 09 AIDS Epidemic Update.
  98. (2000). Zinc salts inactivate clinical isolates of herpes simplex virus in vitro,”